Written By: Neat Digital, Research Content Writer
Reviewed By: Natalie Kunsman, M.D., Board-Certified Physician
Last Reviewed: February 10, 2026
RESEARCH USE ONLY: All products are for laboratory research only. Not for human consumption. Tianeptine subject to regulatory restrictions, verify legal status in your jurisdiction.
Tianeptine is not a federally controlled substance in the United States as of September 21, 2026. On July 8, 2026 the DEA published a proposed rule to place it in Schedule I, and the comment period closed on August 7, 2026. No final rule has published. That gap matters to any laboratory holding tianeptine right now, because the proposal would require a Schedule I research registration to continue handling the material. At least 15 states already control it independently of federal action. Nordic Chems blocks orders to 18 states at checkout, including 5 the DEA's list does not name. This guide sets out what is true today, what changes if the rule is finalized, and what documentation a laboratory should hold either way.
What is Tianeptine Research Compliance?
Tianeptine research compliance is the set of procurement, documentation, storage, and access controls a laboratory applies when handling tianeptine as a research material. It covers verifying the material's legal status in the receiving state, retaining batch-level analytical records, restricting physical access to authorized personnel, and reconciling inventory against use logs.
Is Tianeptine a Controlled Substance in 2026?
No. Tianeptine is not scheduled federally. The DEA's own chemical fact sheet, revised May 2026, states that "tianeptine is not federally controlled under the Controlled Substances Act."
That status is under active review. On July 8, 2026 the DEA published a proposed rule in the Federal Register, docket DEA1596, proposing Schedule I placement. The agency made the 3 statutory findings that Schedule I requires: high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under supervision. Comments closed August 7, 2026. As of today no final rule has been issued, so the proposal is pending and the material remains unscheduled at the federal level.
The practical reading for a laboratory: federal status can change on the date a final rule takes effect, not gradually. Procurement planning that assumes 6 months of warning is planning on something the rulemaking process does not promise.
What the Schedule I Proposal Would Change for Laboratories
If finalized as written, anyone handling tianeptine would need a DEA registration to keep handling it. The proposed rule states that any person who "manufactures, distributes, dispenses, imports, exports, engages in research, or conducts instructional activities or chemical analysis with, or possesses" tianeptine would need to be registered with the DEA.
Two paths follow from that, and they are not the same:
| Situation on the effective date | What the proposal requires |
|---|---|
| Already registered with the DEA for another Schedule I material | Submit a registration modification within 90 calendar days of the effective date, and research may continue in the meantime |
| Not registered for any Schedule I material | Apply for registration and stop handling tianeptine until the DEA approves the application |
The second row is the one that catches most commercial and independent laboratories. There is no grace period in it. A laboratory with no existing Schedule I registration would have to stop work on the effective date and wait out an approval process it has not started.
Anyone holding tianeptine should confirm their registration position now rather than after a final rule publishes. The 90-day window only helps facilities that already hold a Schedule I registration for something else.
State restrictions and how they reach your order
State control of tianeptine predates the federal proposal by 8 years and is where most purchasing gets blocked today. The DEA's proposed rule names 15 states that have controlled or banned its sale: Alabama (2021), Arkansas (2022), Florida (2023), Georgia (2024), Indiana (2024), Kentucky (2023), Louisiana (2024), Maryland (2024), Michigan (2018), Minnesota (2023), Mississippi (2023), Ohio (2022), Oklahoma (2019), Tennessee (2022), and Virginia (2024). The rule prefaces that list with "including," so treat it as a floor, not a complete register.
State law moves faster than this or any other page. Verify your own state before ordering.
How Nordic Chems Enforces State Limits at Checkout
Nordic Chems maintains shipping profiles that block tianeptine orders to 18 states: Alabama, Arkansas, Connecticut, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Mississippi, New Jersey, North Dakota, Ohio, Tennessee, Utah, Virginia, and North Carolina. The block is applied at checkout on the tianeptine sodium capsule and tianeptine powder listings rather than left to the buyer to self-police.
Comparing that list against the DEA's gives a useful picture of how vendors handle the margins:
| Category | States |
|---|---|
| On both the DEA list and the Nordic Chems block list | Alabama, Arkansas, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Mississippi, Ohio, Tennessee, Virginia |
| Blocked by Nordic Chems, not named in the DEA list | Connecticut, New Jersey, North Dakota, Utah, North Carolina |
| Named in the DEA list, check before ordering | Maryland, Oklahoma |
Here is a position most vendors will not take: a restricted-state list is a better compliance signal than a certificate library. Certificates are cheap to post and hard to falsify only if you check them. A checkout block costs the vendor revenue on every order it refuses, which is exactly why few competitors publish one. When qualifying a supplier, ask which states they refuse and compare the answer against your own state statute. A vendor that cannot name its blocked states does not have shipping controls, it has a disclaimer.
What Documentation Should Arrive with a Tianeptine shipment?
At minimum: a certificate of analysis carrying the batch or lot number and the test date, safety and handling information, and identification data that matches what you ordered. Anything less leaves you unable to tie the material in front of you to a specific analytical record.
Certificate of analysis and batch traceability
Nordic Chems issues certificates as PDFs with the analytical graphs included rather than transcribed values, and each one carries the batch or lot number and the test date. Buyers match a certificate to the exact batch they received by emailing their order number to support@nordicchems.is. Testing is performed by 2 named third-party laboratories, BioRegen Labs in Houston, Texas and Janoshik Analytical in Prague, Czech Republic, using HPLC, mass spectrometry, and LC-MS chromatography with retention time and peak analysis. Heavy metals screening runs on the same sample when a buyer requires it. Material is tested at the incoming raw stage against a 99% purity threshold, and batches that fall below it are not used. Manufacturing operates under ISO 9001:2015, certificate number C2024-01140, covering custom synthesis, quality testing, and distribution.
Ask where that chain stops. Nordic Chems has 20 batches tested to date across more than 1 year of operation and 10,600 orders shipped, with a 25% all-time repeat purchase rate. BioRegen is working toward ISO/IEC 17025 accreditation and does not hold it yet, which is worth knowing and worth asking every vendor you use. Most will not answer the question. A supplier that tells you where its accreditation stands is giving you something you can verify, which is more useful than a claim you cannot.
Vendor qualification in 2026
Four questions separate suppliers, and none of them are about price:
- Which states do you block, and at what point in the order?
- Can I match a certificate to my specific batch, and what is the process?
- Which laboratories run your analysis, where are they, and what is their accreditation status?
- What is your documented response when a batch fails specification?
Nordic Chems requires buyers to read the full terms and conditions and declare trained professional status before checkout completes, vets every order before fulfillment, and permanently blocks accounts that breach those terms. Read the quality standards and supplier documentation pages before placing a first order, and keep vendor correspondence, purchase orders, and delivery records with the certificate.
Storage, Access Control, and Inventory records
Tianeptine should be held in a restricted-access area with a locked cabinet, a limited and documented key or code list, and a log of every removal. The controls below are ordinary laboratory safety practice and would become a registration condition if Schedule I placement is finalized.
Storage conditions the supplier specifies: cool, dry, container tightly closed, kept locked or in an area accessible only to qualified or authorized personnel. Material ships induction sealed and desiccated, in tamper-evident packaging labelled Nordic Chems.
Chain of custody records should capture the date, the time, the person, the quantity, and the purpose for every movement from receipt through storage, use, and disposal. Two signatures on each transfer, the person removing the material and a supervising witness, gives you a record that survives an audit. Reconcile physical quantities against the use log monthly and investigate any variance the same week you find it.
Authorization is a separate control from training, and laboratories routinely collapse the two. Access credentials should go only to personnel with a documented need. Training should cover handling, emergency response, the documentation you expect, and the specific state and federal position on the material, and it should be repeated when that position changes. A 2026 training deck that still says tianeptine is unscheduled will be wrong the day a final rule takes effect.
How Often Should a Laboratory Audit its Tianeptine Inventory?
Monthly for physical reconciliation, annually for the written policy. Monthly counts catch variance while the records are recent enough to explain it. Annual policy review catches regulatory drift.
Written policy should name authorized uses, prohibited activities, documentation requirements, the escalation path, and the consequences for breach. Tie the review date to the federal docket rather than the calendar: if DEA1596 produces a final rule, the policy needs revision that month, not at the next annual cycle.
DISCLAIMER: All products referenced on this site are for Research and Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Additional Notice: Tianeptine is subject to regulatory restrictions in multiple jurisdictions. This content addresses laboratory research only. Institutional credentials required. Verify legal status before purchase.
Conclusion
Advancing tianeptine research requires unwavering commitment to ethical standards, regulatory compliance, and institutional accountability at every stage of the research process. Institutions must prioritize implementing comprehensive frameworks that encompass secure procurement from certified suppliers like Nordic Chems, rigorous study design protocols, and multi-layered security measures. By establishing clear policies, conducting regular audits, and fostering cultures of transparency, research facilities can contribute meaningfully to scientific knowledge while actively preventing diversion and misuse. The collaborative effort between suppliers, researchers, regulatory agencies, and ethics committees creates a protective ecosystem that enables legitimate scientific inquiry to flourish responsibly.
Take decisive action today by reviewing your institution's current tianeptine handling protocols against the standards outlined in this guide. Verify that your procurement processes involve only certified research-grade suppliers, ensure all personnel receive mandatory ethics and safety training, and implement robust inventory management systems with regular reconciliation procedures. Schedule comprehensive security audits, update institutional policies to reflect current regulatory requirements, and establish clear reporting mechanisms for concerns. Through proactive compliance and ethical vigilance, your research institution can advance valuable tianeptine studies while maintaining the highest standards of scientific integrity and public health protection.
DISCLAIMER: All products referenced on this site are for Research and Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Additional Notice: Tianeptine is subject to regulatory restrictions in multiple jurisdictions. This content addresses laboratory research only. Institutional credentials required. Verify legal status before purchase.
FAQs
What makes tianeptine a research-only compound?
Tianeptine carries research-only designation due to regulatory classifications that restrict its use to approved scientific studies. It cannot legally be sold for human consumption outside controlled clinical trials with proper institutional oversight.
How do I verify a tianeptine supplier's legitimacy?
Legitimate suppliers require institutional verification, research credentials, and approved protocol documentation before processing orders. They provide comprehensive Certificates of Analysis with each shipment confirming purity and molecular structure specifications.
What training is required for personnel handling tianeptine?
Personnel must complete mandatory training covering safety procedures, ethical responsibilities, regulatory compliance, and emergency response protocols. Only individuals with appropriate credentials and demonstrated competence receive authorization after completing required training modules.
How often should tianeptine inventory audits occur?
Inventory audits should be conducted at least monthly to reconcile physical quantities against usage logs. Regular audits identify discrepancies promptly and maintain accurate chain of custody documentation throughout the compound lifecycle.
What should institutions include in tianeptine research policies?
Policies must define authorized uses, prohibited activities, documentation requirements, and escalation procedures for violations. They should establish consequence frameworks ranging from additional training to termination while addressing procurement, storage, and disposal procedures.
